Literature DB >> 24243011

Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design.

Craig W Hendrix1.   

Abstract

HIV pre-exposure prophylaxis trials with antiretroviral drugs have been variably successful. Even trials demonstrating the best efficacy leave room for improvement. Pharmacological data illuminate several sources of outcome variability, especially the impact of poor adherence, which is critical to manage PrEP in the clinic and to develop the next generation of PrEP candidates.
Copyright © 2013 Elsevier Inc. All rights reserved.

Mesh：

Substances：

Year:  2013        PMID： 24243011     DOI： 10.1016/j.cell.2013.09.030

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  45 in total

Review 1.  Topical Microbicides in HIV Prevention: State of the Promise.

Authors:  Jared M Baeten; Craig W Hendrix; Sharon L Hillier
Journal:  Annu Rev Med       Date:  2019-10-15       Impact factor: 13.739

2.  Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.

Authors:  Ariane van der Straten; Ashley Mayo; Elizabeth R Brown; K Rivet Amico; Helen Cheng; Nicole Laborde; Jeanne Marrazzo; Kristine Torjesen
Journal:  AIDS Behav       Date:  2015-05

3.  Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).

Authors:  Jennifer A Robinson; Mark A Marzinke; Edward J Fuchs; Rahul P Bakshi; Hans M L Spiegel; Jenell S Coleman; Lisa C Rohan; Craig W Hendrix
Journal:  J Acquir Immune Defic Syndr       Date:  2018-02-01       Impact factor: 3.731

4.  Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Authors:  Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2016-09-19       Impact factor: 2.205

5.  Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.

Authors:  Surulivelrajan Mallayasamy; Ayyappa Chaturvedula; Michael J Fossler; Mark Sale; Vineet Goti; Namandje N Bumpus; Mark A Marzinke; Craig W Hendrix; Jessica E Haberer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

6.  Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.

Authors:  Peter L Anderson; David V Glidden; Lane R Bushman; Walid Heneine; J Gerardo García-Lerma
Journal:  J Antimicrob Chemother       Date:  2014-05-26       Impact factor: 5.790

7.  Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.

Authors:  Manjula Gunawardana; Mariana Remedios-Chan; Christine S Miller; Rob Fanter; Flora Yang; Mark A Marzinke; Craig W Hendrix; Martin Beliveau; John A Moss; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

8.  Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.

Authors:  Pavan Kumar Prathipati; Subhra Mandal; Gregory Pon; Renuga Vivekanandan; Christopher J Destache
Journal:  Pharm Res       Date:  2017-09-13       Impact factor: 4.200

9.  Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana.

Authors:  Deborah A Gust; Fatma Soud; Felicia P Hardnett; Charles K Malotte; Charles Rose; Poloko Kebaabetswe; Lebogang Makgekgenene; Faith Henderson; Lynn Paxton; Tebogo Segolodi; Peter H Kilmarx
Journal:  J Acquir Immune Defic Syndr       Date:  2016-12-15       Impact factor: 3.731

10.  Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.

Authors:  Jessica E Justman; Gonasagrie Lulu Nair; Craig W Hendrix; Jeanna M Piper; Mark A Marzinke; James Y Dai; Zhenyu Pan; Beth Galaska; Lisa Levy; Jill L Schwartz; Bhavna Balar; Ratiya P Kunjara Na Ayudhya; Ivy Mushamiri; Ian McGowan; Charlene S Dezzutti
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.